logo

For the Inventor, By the Inventor

Buffalo, NY, United States of America

Health Research, Inc.


USPTO Granted Patents = 314

% Expired Patents = 24.8



Trademarks = 7

Forward Citations = 5,614

Loading Chart...
Loading Chart...

413 inventors (with patents filed for the assignee):

goldMedal Ravindra Kumar Pandey (39 out of 47 patents)

silverMedal Thomas J Dougherty (36 out of 39 patents)

bronzeMedal William R Potter (28 out of 28 patents)

4.  Enzo Paoletti (21 out of 64 patents)

5.  John R Subjeck (10 out of 10 patents)

6.  Yasmin M Thanavala (10 out of 11 patents)

7.  Kenneth R Weishaupt (10 out of 10 patents)

8.  Ben K Seon (9 out of 9 patents)

9.  Xiang-Yang Wang (9 out of 9 patents)

10.  Sean Philpott (7 out of 7 patents)

11.  Barbara Weiser (7 out of 7 patents)

12.  Harold Burger (7 out of 7 patents)

13.  Sek Wen Hui (7 out of 7 patents)

14.  Gerwin Schalk (6 out of 9 patents)

15.  Khurshid Guru (6 out of 6 patents)


Core Competencies:
Combination Therapy
T Cell Receptors
Cancer Treatment
Anti-Survivin Antibodies
Prostate Cancer
Immunotherapy
Nanoplatforms
Viral Infections
Biomarkers
Photosensitizers
Apoptosis Induction
Fluorescence Imaging

314 patents:

1. 12758542 - METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMA (2026-10-13),
2. 12673032 - EXPLOITING ESTROGEN RECEPTOR BETA AND TP53 INTERACTION AS A NEW THERAPEUTIC STRATEGY FOR CANCER (2026-07-07),
3. 12594271 - Combination therapy for cancer (2026-04-07),
4. 12551498 - Treatment of P53-deficient cancers (2026-02-17),
5. 12371470 - Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen (2025-07-29),
6. 12337004 - Coumarin-modified androgens for the treatment of prostate cancer (2025-06-24),
7. 12275946 - Compositions and methods for rapid cloning of t-cell receptors (2025-04-14),
8. 12133713 - Clinical intravital microscope (2024-11-05),
9. 12125206 - In vivo magnetic resonance image distortion check apparatus and method (2024-10-22),
10. 12115215 - Composition and method for generating immunity to borrelia burgdorferi (2024-10-15),
11. 12115207 - Treatment of inflammation (2024-10-15),
12. 11951454 - Fluid treatment apparatus, systems, and methods (2024-04-09),
13. 11779256 - Rapid mapping of language function and motor function without subject participation (2023-10-10),
14. 11773181 - Anti-survivin antibodies for cancer therapy (2023-10-03),
15. 11771750 - Composition and method for generating immunity to (2023-10-03),
Company Overview
Health Research, Inc., based in Buffalo, NY, specializes in advancing cancer therapy through innovative research and development. The organization focuses on combination therapies and immunotherapy, leveraging technologies such as T cell receptors and anti-survivin antibodies to enhance treatment efficacy. Their work addresses various cancer types, including prostate cancer, and explores the use of nanoplatforms and strategies for combating viral infections, contributing significantly to the field of oncology and therapeutic advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

314 Patents

#1 in Buffalo, NY

#95 in New York

#1,397 in US

#2,857 in the World

Buffalo, NY (US)
Buffalo, NY, United States of America

Health Research, Inc.

Forward Citations = 5,614

413 inventors:

goldMedal Ravindra Kumar Pandey (39 out of 47 patents)

silverMedal Thomas J Dougherty (36 out of 39 patents)

bronzeMedal William R Potter (28 out of 28 patents)

4.  Enzo Paoletti (21 out of 64 patents)

5.  John R Subjeck (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Health Research, Inc.. Retrieved from https://idiyas.com/company/health-research

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…